Medical Services Develops New
Diagnostic Test Kit For Prostate Cancer
 

February 11, 2005
Medical Services International Inc (Pinksheets: MSITF) is pleased to announce that it has developed a new diagnostic test kit for diagnosing Prostate Cancer. The test is a one-step prostate specific antigen test (PSA). It gives results within 20 minutes. The results are easy to read and require no additional instrumentation or reagents and is very accurate (greater than 99%). The PSA test acts as a screening tool for cancer of the prostate.

Currently the tests for prostate cancer require the individual to visit a laboratory after being examined by a physician. Results are not obtained for over 24 hours or more when the testing is completed by laboratories. This test can be administered in a physicians office and the results are obtained prior to leaving the doctors office.

The Company has begun testing of the kit to obtain regulatory approval. The first area where testing is ongoing is China. The Company will also begin the process to obtain regulatory approval in the United States. There is a significant market for an early screening test for prostate cancer in men over 45 years of age.

The Company will continue to use its facilities and scientists to develop new test kits where market studies show there is a potential for great demand. By diversifying its types of diagnostic test kits, the company is in the position that a change in demand for a particular test kit will not affect the overall performance of the Company.

About VScan ™

The VScan™ rapid test kit is a single use, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever and West Nile,  Syphilis, and Prostate Cancer. The kits cannot be sold in Canada.

For further information contact:
Robert Talbot at 780-430-6363 or
Bill Whitehead, Jr., 416-822-5883

Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF".